(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of 19.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Meiragtx Holdings's revenue in 2026 is $79,758,000.On average, 9 Wall Street analysts forecast MGTX's revenue for 2026 to be $5,421,916,724, with the lowest MGTX revenue forecast at $26,591,896, and the highest MGTX revenue forecast at $18,145,908,565. On average, 8 Wall Street analysts forecast MGTX's revenue for 2027 to be $13,561,737,523, with the lowest MGTX revenue forecast at $6,577,220,436, and the highest MGTX revenue forecast at $25,236,093,110.
In 2028, MGTX is forecast to generate $9,464,692,535 in revenue, with the lowest revenue forecast at $3,474,153,383 and the highest revenue forecast at $14,899,018,934.